Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 for T-Cell Recovery After Cord Blood Transplant
NCT03600896Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Nov 2023
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of recombinant human interleukin-7 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), Chronic Myeloid Leukemia (CML), myeloproliferative neoplasm (MPN), graft-versus-host disease (GVHD), sponsored by University of Texas MD Anderson Cancer Center. Planned start Nov 2018; status: withdrawn.
02
Drugs
recombinant human interleukin-7
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Chronic Myeloid Leukemia (CML)myeloproliferative neoplasm (MPN)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03600896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03600896.